Skip to main content
Unchecking box will stop auto data updates
TSX Real-Time Last Sale CAD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 15.00
Day High 15.17
Open:15.04
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Description
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company earns most of its revenue from the United States.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

HLS Therapeutics Announces Q3 2019 Financial Results
- CNW Group - Thu Nov 7, 5:30AM CST
CNW Group - CMTX
Thu Nov 7, 5:30AM CST
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces its financial results for the three- and nine-month periods ended September 30, 2019 ("Q3 2019" and "YTD 2019"). All amounts are in thousands of United States ("U.S.") dollars unless otherwise stated.
HLS Therapeutics to Host Q3 2019 Financial Results Conference Call
- CNW Group - Thu Oct 24, 5:30AM CDT
CNW Group - CMTX
Thu Oct 24, 5:30AM CDT
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company specializing in central nervous system and cardiovascular markets, announces that it will release its third quarter 2019 financial results by press release at 6:30 a.m. Eastern Time on Thursday, November 7, 2019. The Company will hold a conference call that same day at 8:30 a.m. Eastern Time to discuss its results. The call will be hosted by Mr. Greg Gubitz, Chief Executive Officer, Mr. Gilbert Godin, President and Chief Operating Officer and Mr. Tim Hendrickson, Chief Financial Officer.
HLS Therapeutics announces Health Canada grants medical device license for White Blood Cell Point-of-Care Device to be marketed as CSAN® PRONTO(TM)
- CNW Group - Thu Oct 17, 5:30AM CDT
CNW Group - CMTX
Thu Oct 17, 5:30AM CDT
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that Health Canada has granted a medical device license for the Athelas One WBC System for use as a point-of-care device indicated for quantitative determination of white blood cells (WBC) and neutrophil percentages in capillary or venous whole blood. This medical device may help enhance and simplify the mandatory safety blood monitoring process for Treatment Resistant Schizophrenia ("TRS") patients that are prescribed Clozaril(®) (clozapine). HLS intends to launch the device as part of its current Clozaril Support and Assistance Network ("CSAN(®)") program under the name, CSAN(® )ProntoTM.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 14.50 +3.86% increase
on 10/21/19
Period Open:14.50
Price movement based on the high, low and last over the given period.
15.38 -2.08% decrease
on 11/07/19
+0.56 (+3.86%) increase
since 10/11/19
3-Month 12.91 +16.65% increase
on 09/04/19
Period Open:15.48
Price movement based on the high, low and last over the given period.
15.55 -3.15% decrease
on 08/12/19
-0.42 (-2.71%) decrease
since 08/09/19
52-Week 12.91 +16.65% increase
on 09/04/19
Period Open:16.09
Price movement based on the high, low and last over the given period.
18.30 -17.70% decrease
on 07/22/19
-1.03 (-6.40%) decrease
since 11/09/18

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2019.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).